AGN-199201 for the Treatment of Erythema With Rosacea

Study Identifier
199201-002
CT.gov Identifier
NCT01735201
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dermatology - Other
    • Study Drug
  • AGN-199201 Dose A
  • AGN-199201 Dose B
  • AGN-199201 Dose C
  • AGN-199201 Vehicle
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Redness of the skin caused by rosacea
    Exclusion Criteria:
    * ≥3 inflammatory lesions * Laser light-source or other energy based therapy in the last 6 months * Any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days

    Protocol Summary

    This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

    Study Locations

    Location
    Status
    Location
    Austin, Texas, United States
    Status
    Not applicable